about
Impaired Pituitary Axes Following Traumatic Brain InjuryDiabetes in Patients With Acromegaly.An unusual syncope.Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.Etiology of Hypopituitarism in Adult Patients: The Experience of a Single Center Database in the Serbian Population.Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging studyBoth low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly menReevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of DiseaseAssociation of diurnal patterns in salivary cortisol with all-cause and cardiovascular mortality: findings from the Whitehall II study.Diagnostics, treatment, and follow-up in craniopharyngioma.Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide studyAcromegaly: the disease, its impact on patients, and managing the burden of long-term treatment.The role of androgens and estrogens on healthy aging and longevity.Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients.Growth Hormone and Treatment Controversy; Long Term Safety of rGH.Tumor origin and growth pattern at diagnosis and surgical hypothalamic damage predict obesity in pediatric craniopharyngioma.A consensus on the diagnosis and treatment of acromegaly complications.Patient perspectives on the impact of acromegaly: results from individual and group interviews.Adrenal cortical insufficiency--a life threatening illness with multiple etiologies.Pituitary apoplexy presenting as myocardial infarction.A review of guidelines for use of growth hormone in pediatric and transition patients.Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsChildhood craniopharyngioma.Management options for persistent postoperative acromegaly.Oxidative stress and the ageing endocrine system.Diagnosis and treatment of growth hormone deficiency in adults.Diagnosis of acromegaly: state of the art.Childhood craniopharyngioma: treatment strategies and outcomes.Can side effects of steroid treatments be minimized by the temporal aspects of delivery method?Emerging drugs for Cushing's disease.New therapeutic agents for acromegaly.Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.Preoperative Stratification of Transsphenoidal Pituitary Surgery Patients Based on Surgical Urgency.Ischemic stroke after radiation therapy for pituitary adenomas: a systematic review.The safety of treatments for prolactinomas.Risk-adapted treatment and follow-up management in childhood-onset craniopharyngioma.The chronic syndromes after previous treatment of pituitary tumours.Surgical outcomes in patients with Cushing's disease: the Cleveland clinic experience.Sex differences in the prevalence of metabolic syndrome and its components in hypopituitary patients: comparison with an age- and sex-matched nationwide control group.
P2860
Q26799418-3525CF19-7C65-4E4E-9E78-78EC70184C97Q30238646-10868DB1-A442-442C-99D1-D6F77015EE57Q33161109-BDDF8A9A-126C-4D3D-9A96-EA69778ED057Q33569037-E135C4E8-65F3-489A-9907-A3DB277D520AQ33862326-9CCB729B-24E5-4A99-BCB1-2C935B108234Q34468113-482E5204-0F4F-4FA8-BB8E-883D771A3A14Q34647846-DA1FCF54-5063-4AF9-A588-171DE3F82893Q34815007-8CE800BA-23C8-47B4-A212-FE19D682028CQ34894329-6E5BCF49-A7DF-410D-A45E-A8BCD0D318BDQ35971790-94792925-A8BB-45D9-A0A9-508871468946Q35981653-9054C2F2-730B-4C37-A509-31FEB559C07CQ36164322-FCAE0663-EA6E-4097-AD7A-4855EF54F19BQ36563998-CF03BB90-E146-486F-82AE-9753B9E4442EQ36796228-53C982AA-DF71-4EDB-99D0-5C5ADA0605CDQ36915085-29280B9D-9B85-4B0C-8E4E-D21F90414FC7Q36918629-C9BBF824-7660-4DB3-8100-744FAF8EBDD2Q36935031-0A143258-5D76-46A2-9A27-124F669CED58Q37061155-4FEEEBDC-4ED9-4B6A-B0E2-AD3398BE7BB5Q37487867-5DA64CAE-0B85-46B3-A525-6944498F733EQ37592058-D1AC71ED-0B42-4A6E-96AF-A5D57D252E97Q37703719-BE636D00-ED58-4E62-8219-31A1C665776DQ37978219-21AE76B1-F811-4D8D-A7EC-31D21216AF3CQ37980741-1F00FA10-22C5-4948-94A8-470238B8661AQ38017149-33CC6EFF-758A-4C5F-A37B-03E4FC37DF87Q38049832-84C34D76-2D7F-4AC6-8616-0B788D5D5F51Q38084435-72D42449-4EEB-4787-9368-1413E0897308Q38102923-AFAC795E-5709-49C0-8D19-78E5D6761909Q38131055-0CCE2B17-6427-4434-878C-DD9B88B017BDQ38178752-DCB69FB6-A4C2-4FC9-BB12-A94DB1E3693DQ38254723-FB445F4F-2771-4BD8-8DAD-2CF7D83708E7Q38505947-E74887B9-E6F5-4A91-95FC-34195D33109AQ38648739-B4E515D2-D321-41B5-AA7E-12A4981A4639Q38667209-7B44CD32-0051-4E92-903C-2074DAFC4958Q38682306-2D90461D-B11C-425E-98CC-A9089F092F12Q38703363-CED54B18-CEC7-4BA9-A61A-F777BA5F5219Q38726058-C86933B1-D906-4DB0-8418-774E5AA615FDQ38776792-3071920F-DF29-404E-A9B6-FB0FB0599E64Q38853092-351A7234-99F9-4C61-B892-8D1A07B2DB96Q38925788-BC3CB646-6E8F-4EE7-ABE5-105601E1405CQ39438997-C2EE4746-5065-42C4-9159-D933A06F01DA
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mortality in patients with pituitary disease.
@en
Mortality in patients with pituitary disease.
@en-gb
Mortality in patients with pituitary disease.
@nl
type
label
Mortality in patients with pituitary disease.
@en
Mortality in patients with pituitary disease.
@en-gb
Mortality in patients with pituitary disease.
@nl
prefLabel
Mortality in patients with pituitary disease.
@en
Mortality in patients with pituitary disease.
@en-gb
Mortality in patients with pituitary disease.
@nl
P2093
P356
P1433
P1476
Mortality in patients with pituitary disease.
@en
P2093
Andrew A Toogood
Andrew S Bates
Aurora Aragon-Alonso
Mark Sherlock
Michael C Sheppard
P304
P356
10.1210/ER.2009-0033
P577
2010-01-19T00:00:00Z